drugset / Trial / NCT00320814

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

NCT00320814

Phase 1 Completed 5 enrolled Regeneron Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.

Timeline

Start
2006-04
Primary completion
2006-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 4 mg Intravitreal